Buprenorphine (or Suboxone®) and injectable Naltrexone (Vivitrol) are key resources to address the increase in opioid use disorders and overdose deaths. However, treatment organizations have struggled with a variety of issues related to expanding medication-assisted treatment (MAT).
Aim of the Opioid MAT Expansion project
Increase buprenorphine and injectable naltrexone use through:
Method
NIATx, based at the University of Wisconsin–Madison, will work with substance use disorder (SUD) treatment providers and health systems in Florida, Ohio and Wisconsin to design and implement strategies to expand MAT capacity at their organizations.
This project will address the issue of prescriber recruitment by employing a group of practices, the Prescriber Recruiting Bundle (PRB). The PRB includes:
Project Plan
The study will take place over 2 years. Treatment sites will be divided into control and intervention groups. For the intervention group, NIATx coaches will engage with contacts at SUD treatment sites and health systems. The coach is an expert in prescriber recruitment and organizational change who will help organizations make, sustain, and spread PRB practices. Coaches consult with executive leaders, physician recruiters, and clinical staff and offer feedback based on user assessment tools and previous conversations with the organization. Coaches help organizations:
Coaching is provided during a site visit, monthly coach calls, and e-mails as needed. Control sites will receive PRB resources, however will not receive technical assistance from the coaches.
This project is supported by a grant from the National Institute on Drug Abuse (NIDA).